Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11480751 | 0.87 | GABRA1 (0.36) | DPP4TAAR1 | |
| SCHEMBL38656820 | 0.80 | PNMT (0.48) | DPP4PNMTTAAR1KDM4ESMN1; SMN2 | |
| SCHEMBL29098931 | 0.80 | PNMT (0.48) | DPP4PNMTTAAR1KDM4ESMN1; SMN2 | |
| SCHEMBL15247 | 0.79 | PNMT (0.63) | DPP4PNMTTAAR1KDM4ESMN1; SMN2 | |
| SCHEMBL29405036 | 0.79 | PNMT (0.63) | DPP4PNMTTAAR1KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28493658 | 0.78 | PNMT (0.46) | DPP4PNMTTAAR1KDM4ESMN1; SMN2 | |
| SCHEMBL96154 | 0.78 | GABRA1 (0.45) | TAAR1KDM4E | |
| SCHEMBL11346922 | 0.77 | PNMT (0.41) | DPP4PNMTTAAR1KDM4ESMN1; SMN2 | |
| SCHEMBL7687789 | 0.76 | APOBEC3G (0.43) | DPP4TAAR1CYP2A6 | |
| SCHEMBL360936 | 0.76 | FDPS (0.41) | TAAR1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118354781-A | Peptide inhibitors of interleukin-23 receptor | 西兰制药公司 | 2024-07-16 | — | — | CN | claimed |
| WO-2023099669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2023-06-08 | — | — | WO | claimed |
| US-20040260084-A1 | Novel c-3 s/o-and s/n formaldehe acetal derivatives of cephalosporins and their use as antibotics | PFAENDLER HANS R (DE) | 2004-12-23 | — | — | US | claimed |
| EP-1444237-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | Pfaendler, Hans Rudolf (DE) | 2004-08-11 | — | — | EP | claimed |
| WO-2003042219-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | PFAENDLER HANS RUDOLF (DE) | 2003-05-22 | — | — | WO | claimed |
| EP-0382411-B1 | Delivery of cytotoxic agents | LILLY CO ELI (US) | 1994-12-07 | — | — | EP | claimed |
| WO-1994001137-A1 | METHOD FOR DELIVERY OF CYTOTOXIC AGENTS AND COMPONENTS THEREOF | HYBRITECH INCORPORATED (US) | 1994-01-20 | — | — | WO | claimed |
| EP-0382411-A2 | Delivery of cytotoxic agents | ELI LILLY AND COMPANY (US) | 1990-08-16 | — | — | EP | claimed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | claimed |
| US-4172199-A | ISOOXACEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1979-10-23 | — | — | US | claimed |
| US-4171439-A | Antibacterial analogs of isocephalosporins | BRISTOL-MYERS COMPANY (US) | 1979-10-16 | — | — | US | claimed |
| US-4171438-A | 0-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1979-10-16 | — | — | US | claimed |
| US-4166906-A | ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1979-09-04 | — | — | US | claimed |
| US-4166905-A | ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1979-09-04 | — | — | US | claimed |
| US-4144333-A | Monocyclic beta-lactams with antibacterial activity | SMITHKLINE CORPORATION (US) | 1979-03-13 | — | — | US | claimed |
| US-4118566-A | Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-10-03 | — | — | US | claimed |
| US-4113946-A | Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-09-12 | — | — | US | claimed |
| US-4112230-A | Δ2,3 -1,4 Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | claimed |
| CN-118354781-A | Peptide inhibitors of interleukin-23 receptor | 西兰制药公司 | 2024-07-16 | — | — | CN | disclosed |
| US-4011216-A | Δ2,3-0-2-Isocephem-4-carboxylic acid and derivatives thereof as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260084-A1 | Novel c-3 s/o-and s/n formaldehe acetal derivatives of cephalosporins and their use as antibotics | CBR3, CBR1, SULT1E1 | DPP4 3858/4885PNMT 2788/4885TAAR1 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.